Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following PDMR share transactions.

The Company was notified on 10 May 2022 that following his decision to participate in the Deferred Share Bonus (DSB), Chris Meredith, who is a Director and PDMR, undertook the following transactions:

·    The exercise of 395,355 options from the Long-Term Incentive Plan (LTIP).

·    The exercise of 34,608 options from the existing Deferred Annual Bonus Plan (DAB).

·    Elected to receive an additional 543 dividend shares which were earned during the holding period under the terms of the DAB.

·    The exercise of 23,415 Ordinary Shares of 5p from the existing DSB and the award of 56,785 shares under the DSB.

·    The sale of 246,384 Ordinary Shares of 5p each on 10 May 2022 at a share price of 271.5p per Ordinary Share by way of an off-market sale. The proceeds from the sale of the shares was used to purchase shares in the DSB and cover the tax payable on the above exercises.

The Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares") between 10 and 12 May 2022, at an average price of 270.5p on behalf of Chris Meredith as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf.

As a result of these transactions Chris Meredith's beneficial interest in the Company increased and his overall holding is as follows:

The Company was also notified on 12 May 2022 that following the decision by Eddie Johnson, who is a Director and PDMR, to participate in the DSB the Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares")  between 10 and 12 May 2022, at an average price of 270.5p on behalf of Eddie Johnson as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf. Eddie Johnson was awarded of 17,225 shares under the DSB.

As a result of these transactions Eddie Johnson's beneficial interest in the Company increased and his overall holding is as follows:

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

-End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.